Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Shareholders' Equity (Tables)

v3.25.1
Shareholders' Equity (Tables)
12 Months Ended
Dec. 31, 2024
Shareholders' Equity [Abstract]  
Schedule of Information Regarding Outstanding Warrants to Purchase Shares

The following table summarizes information regarding outstanding warrants to purchase the Company’s ordinary shares as of December 31, 2024:

 

  Issuance date  

Number of

outstanding

Warrants

   

Exercise

price per

warrant

 
               
  January 2020     23,838,038     $ 0.12  
  February 2020     11,250,000     $ 0.05  
  July 2020     29,419,890     $ 0.08  
  August 2021     10,500,000     $ 0.07  
  December 2021     10,500,000     $ 0.07  
  January 2023     28,636,500     $ 0.02  
  November 2023     771,366,900     $ 0.01  
  August 2024     1,774,285,800     $ 0.01  
        2,659,797,128          
Schedule of Weighted Average Exercise Prices and Modification in Option Plans of Employees, Directors and Consultants

The following table summarizes Company's option activity during the year ended December 31, 2024: 

 

      Number of
options
    Weighted
average
exercise
price
    Weighted
average
remaining
contractual
terms
(in years)
    Aggregate
intrinsic
value
 
                           
  Outstanding at December 31, 2023     82,477,000       0.04       8.40      
       -
 
  Grants     50,000,000       0.00       9.85      
-
 
  Forfeited/expired     (7,648,000 )    
-
     
-
     
-
 
                                   
  Outstanding at December 31, 2024     124,829,000       0.03       7.1      
-
 
                                   
  Vested and expected to vest at December 31, 2024     124,829,000       0.03       7.1      
-
 
                                   
  Exercisable at December 31, 2024     46,019,625       0.07       5.9      
-
 
Schedule of Fair value of Company’s Share Options Granted

The fair value of the Company’s share options granted was estimated using the binomial option pricing model using the following range assumptions:

 

Description   2024   2023   2022
             
Risk-free interest rate   4.64%-5.09%   3.95%-3.96%   1.41-3.08%
Expected volatility   83.40%-83.94%   84.30%-84.76%   83.98-84.26%
Dividend yield   0%   0%   0%
Contractual life (in years)   9.75-10   10   10
Early Exercise Multiple (Suboptimal Factor)   2.5   2.5   2.5-3
Schedule of Expenses Recognized Financial Statements Expenses recognized in the financial statements:
    Year ended December 31,  
    2024     2023     2022  
                   
Research and development   $ 75     $ 83     $ 137  
General and administrative (*)     287       178       126  
      362       261       263  

 

(*) Including $112 share based compensation for services provided in 2024, refer to note 9(b)(4).